Rebecca Spain

Dr. Rebecca Spain


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Gait & Posture
Verified
Journal Article
Closed access
RSRebecca Spain
Rebecca Spain
RGR.J. St. George
R.J. St. George
ASA. Salarian
A. Salarian
MMM. Mancini
M. Mancini
JWJ.M. Wagner
J.M. Wagner
DBD. Bourdette
D. Bourdette

1 September 2017 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
RSRebecca Spain
Rebecca Spain
KPKatherine Powers
Katherine Powers
CMCharles Murchison
Charles Murchison
EHElizabeth Heriza
Elizabeth Heriza
KWKimberly Winges
Kimberly Winges
DBDennis Bourdette
Dennis Bourdette
Objective: To determine whether lipoic acid (LA), an endogenously produced antioxidant, slowed the whole-brain atrophy rate and was safe in secondary progressive MS (SPMS). Methods: Patients with SPMS aged 40–70 years enrolled in a single center, 2-year, double-blind, randomized trial of daily oral 1,200 mg LA vs placebo. Primary outcome was change in annualized percent change brain volume (PCBV). Secondary outcomes were changes in rates of atrophy of segmented brain, spinal cord, and retinal substructures, disability, quality of life, and safety. Intention-to-treat analysis used linear mixed models. Results: Participation occurred between May 2, 2011, and August 14, 2015. Study arms of LA (n = 27) and placebo (n = 24) were matched with mean age of 58.5 (SD 5.9) years, 61% women, mean disease duration of 29.6 (SD 9.5) years, and median Expanded Disability Status Score of 6.0 (interquartile range 1.75). After 2 years, the annualized PCBV was significantly less in the LA arm compared with placebo (−0.21 [standard error of the coefficient estimate (SEE) 0.14] vs −0.65 [SEE 0.10], 95% confidence interval [CI] 0.157–0.727, p = 0.002). Improved Timed 25-Foot Walk was almost but not significantly better in the LA than in the control group (−0.535 [SEE 0.358] vs 0.137 [SEE 0.247], 95% CI −1.37 to 0.03, p = 0.06). Significantly more gastrointestinal upset and fewer falls occurred in LA patients. Unexpected renal failure (n = 1) and glomerulonephritis (n = 1) occurred in the LA cohort. Compliance, measured by pill counts, was 87%. Conclusions: LA demonstrated a 68% reduction in annualized PCBV and suggested a clinical benefit in SPMS while maintaining favorable safety, tolerability, and compliance over 2 years. ClinicalTrials.gov identifier: NCT01188811. Classification of evidence: This study provides Class I evidence that for patients with SPMS, LA reduces the rate of brain atrophy.

1 March 2014 in Gait & Posture
Verified
Journal Article
Closed access
RSRebecca Spain
Rebecca Spain
MMMartina Mancini
Martina Mancini
FHFay B. Horak
Fay B. Horak
DBDennis Bourdette
Dennis Bourdette

16 October 2021 in Kidney International
Verified
Journal Article
Closed access
RSRebecca Spain
Rebecca Spain
NANicole K. Andeen
Nicole K. Andeen
PGPamela C. Gibson
Pamela C. Gibson
MSMary H. Samuels
Mary H. Samuels
CMCynthia D. Morris
Cynthia D. Morris
RARupali S. Avasare
Rupali S. Avasare

6 May 2019 in Current Treatment Options in Neurology
Verified
Journal Article
Closed access
PDF file
CWCarin Waslo
Carin Waslo
DBDennis Bourdette
Dennis Bourdette
NGNora Gray
Nora Gray
KWKirsten Wright
Kirsten Wright
RSRebecca Spain
Rebecca Spain

1 February 2009 in Nature Clinical Practice Neurology
Verified
Journal Article
Closed access
RSRebecca Spain
Rebecca Spain
TLThomas P Leist
Thomas P Leist
ESEduardo A De Sousa
Eduardo A De Sousa